Evidence map›Paper›PMID 40869515›Full record

ReviewJournal of clinical medicine2025

Emerging Technologies and Advanced Strategies in Hemoglobin Defect Screening.

Cindy Zhang, Victoria Crystal Chen, Bremansu Osa-Andrews, Jing Cao

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Cindy ZhangSchool of Engineering and Computer Science, University of Texas Dallas, Richardson, TX 75080, USA.
Victoria Crystal ChenThe Nutritional Sciences and Toxicology Department, University of California Berkeley, Berkeley, CA 94720, USA.
Bremansu Osa-AndrewsCollege of Medicine, University of Florida, Gainesville, FL 32611, USA.ORCID 0000-0002-8910-7749
Jing CaoDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-3163-8897

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemoglobin (Hb) defects, or hemoglobinopathies such as thalassemia and structural Hb variants, are among the most prevalent inherited diseases and are associated with significant mortality and morbidity worldwide. Screening for hemoglobinopathies in the primary care setting plays a critical role in enhancing patient outcomes and advancing population health. It promotes awareness, enables early diagnosis and treatment, supports informed reproductive decisions through genetic counseling, and facilitates access to novel therapies such as genetic modifications. Screening approaches for hemoglobinopathies have evolved to reflect regional prevalence, healthcare infrastructure, and ethical considerations. Varying strategies underscore the necessity of tailoring to local contexts, balancing cost, accuracy, accessibility, and social impact. As global migration reshapes population genetics, flexible and equitable screening frameworks are increasingly essential. This review focuses on practical techniques suitable for the screening of Hb defects in primary care. Recent advances and findings in high-performance liquid chromatography, capillary zone electrophoresis, mass spectrometry, point of care testing, and molecular methodologies are covered. In addition, strategies and approaches in multiple regions in the world are reviewed.

Indexed as

anemiahemoglobin defectspoint of care testingsickle cell diseasethalassemia

Identifiers

PMID40869515
PMCPMC12386643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.